Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 21,025 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune System Disorders Clear all

Conditions: Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Rheumatoid Arthritis
Interventions: adalimumab (up to 9 months exposure), methotrexate; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Asthma
Interventions: 80/2.25 μg Symbicort pMDI, 80/4.5 μg Symbicort pMDI, Foradil Aerolizer 12 μg, 40 μg budesonide HFA pMDI, placebo HFA pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Huntington, California • Long Beach, California • Mission Viejo, California + 17 more

Conditions: Hiv, Adherence, Medication
Interventions: PositiveLinks RX Mobile App, PositiveLinks RX Portal; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Newly Diagnosed Multiple Myeloma
Interventions: AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide, Bortezomib, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 45
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions: KT-474/Placebo, KT-474; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more

Conditions: Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
Interventions: SAR443579; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 7 more

Conditions: Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions: azacitidine, donor lymphocyte infusion; Drug · Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 29 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pregnancy (Unwanted), Sexually Transmitted Disease (STD), HIV Infection, Sexual Behavior
Interventions: #TranscendentHealth, Universal Sexual Health Program; Behavioral
Lead sponsor: Center for Innovative Public Health Research; Other
Eligibility: 14 Years to 18 Years · Female only
Enrollment: 467 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Clemente, California

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 19 Years and older
Enrollment: 1,613 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2012
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: busulfan, melphalan, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV, AIDS, Obesity
Interventions: antiretroviral therapy; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 1
Interventions: Application Use; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 1 Year to 17 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Opioid Withdrawal
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Miami Lakes, Florida • Marlton, New Jersey • New York, New York

Conditions: Hairy Cell Leukemia
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Pueblo, Colorado • Bridgeton, Missouri

Conditions: Hypoglycemia, Pediatric ALL
Interventions: Augmented Reality Headset; Behavioral
Lead sponsor: Thomas Caruso; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Mountain View, California • Palo Alto, California

Conditions: CLL
Interventions: Ofatumumab/HDMP; Drug
Lead sponsor: Januario Castro, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: La Jolla, California

Conditions: Type I Hypersensitivity
Interventions: Grass MATA MPL; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Interventions: Zilovertamab vedotin, Nemtabrutinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 20
States / cities: Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 15 more

Conditions: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Interventions: Urelumab (BMS-663513); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 9 more

Conditions: Recurrent Plasma Cell Myeloma
Interventions: Dexamethasone, HDAC Inhibitor AR-42, Laboratory Biomarker Analysis, Pomalidomide; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Medical Oncology
Interventions: Copanlisib (BAY80-6946), Itraconazole, Rifampin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Methotrexate, Ponatinib, Ponatinib Hydrochloride, Prednisone, Rituximab, Vincristine, Vincristine Sulfate; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Previously Treated PH + CML
Interventions: Bosutinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 13
States / cities: Los Angeles, California • Deerfield Beach, Florida • Miami, Florida + 6 more

Search by objective public record fields.

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis

A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy

Using Smart Phone Technology to Support HIV Medication Refill Adherence in Virginia

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

#TranscendentHealth: A Text Messaging Pregnancy Prevention Program for Transgender Boys

Consortium for the Longitudinal Evaluation of African Americans With Early Rheumatoid Arthritis (The CLEAR Registry)

Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma

Obesity in HIV After Antiretroviral Therapy

Pilot Study of Connected Diabetes Technology

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)

Prehospital Provider Training With Augmented Reality (AR)

Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors